Annual cost is just the effective monthly times twelve — but which monthly depends on your dose and plan. Flat-rate providers are predictable to multiply; dose-tiered ones aren’t, so we show a range.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Effective monthly | Annual (x12) | Model | Provenance |
|---|---|---|---|---|
| Henry Meds | $179 | ~$2,148 | Flat | secondary |
| NexLife | ~$186 (12mo) – $215 | ~$2,232–$2,580 | Flat | primary |
| Fifty 410 | ~$166–$299 (dose) | ~$1,992–$3,588 | Dose-tiered | primary/sec |
| Mochi Health | ~$278 | ~$3,336 | Membership+add-on | secondary |
At a low maintenance dose, Fifty 410’s annual can be lowest; at a high maintenance dose, flat-rate Henry Meds/NexLife pull ahead. For context, FDA-approved Wegovy self-pay runs ~$4,188/yr (~$349/mo). Prepaid annual plans require paying up front. See total monthly cost.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.